TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.

TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.

Item
http://www.wikidata.org/entity/Q35155635
Neoadjuvant nab-paclitaxel in the treatment of breast cancerDevelopment of Companion DiagnosticsTriple negative breast cancer: looking for the missing link between biology and treatmentsLandscape of neoadjuvant therapy for breast cancerThe accuracy of (18)F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review.Efficiency of fluorodeoxyglucose positron emission tomography/computed tomography to predict prognosis in breast cancer patients received neoadjuvant chemotherapyMulticenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids.nab-Paclitaxel for the treatment of breast cancer: an update across treatment settingsNanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography.¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials.Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers.FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.HER2 imaging in the ZEPHIR study.Do TSH, FT3, and FT4 Impact BAT Visualization of Clinical FDG-PET/CT Images?
P2860

TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.

Item
http://www.wikidata.org/entity/Q35155635
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
TBCRC 008: early change in 18F ...... rimary operable breast cancer.
@ast
TBCRC 008: early change in 18F ...... rimary operable breast cancer.
@en
type
label
TBCRC 008: early change in 18F ...... rimary operable breast cancer.
@ast
TBCRC 008: early change in 18F ...... rimary operable breast cancer.
@en
prefLabel
TBCRC 008: early change in 18F ...... rimary operable breast cancer.
@ast
TBCRC 008: early change in 18F ...... rimary operable breast cancer.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
TBCRC 008: early change in 18F ...... rimary operable breast cancer.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932